End-to-End Control at our State-of-the-Art cGMP Facility

We are building the future of drug delivery at scale. Investing in talent and capacity to develop and manufacture all RITe™ products in-house at our state-of-the-art cGMP facility in the USA.

Faster iteration drives innovation. Our robust in-house formulation, analytical, development and manufacturing capabilities give us the ability to accelerate pipeline development and gain flexibility from clinical to commercial scale.

End-to-end control over our processes provide enhanced quality oversight, mitigates third-party risk, and protects the specialized knowledge we’ve developed to produce the RITe™ Platform.

We are proud to invest in our community and manufacture in the USA to support our promise to develop life-changing medications for the benefit of patients around the world.

Next up